Incyte (INCY) Unveils Fresh Oncology Data, Is The Stock 9% Undervalued?

Incyte (INCY) has moved back into focus after presenting Phase 1 data at the ESMO 2026 Congress on two gastrointestinal oncology assets, along with new combination trials and collaborations that expand its development pipeline.

Recent trading tells a mixed story for Incyte. The share price is up 3.02% over the past week but down 6.37% over the last month and 4.98% over the past quarter, while the year to date share price return of 15.23% and 1 year total shareholder return of 29.60% point to momentum building over a longer window. This is reinforced by a 3 year total shareholder return of 114.95% and 5 year total shareholder return of 74.98% as investors weigh the new oncology data, fresh collaborations and the upcoming Q3 earnings report.

Scan beyond Incyte and see how other oncology-focused biopharma stocks with expanding pipelines line up in the 19 high quality undiscovered gems.

Bulls point to Incyte’s oncology data and Q3 momentum, while bears focus on slowing annual revenue and profit growth. Which side does the current valuation lean toward as the pipeline story meets the numbers?

Most Popular Narrative: 9% Undervalued

At a last close of $116.87 against a narrative fair value of $128.48, Incyte is framed as modestly undervalued, with that gap hinging on how convincingly management turns a Jakafi heavy franchise into a broader portfolio.

The upcoming launches and label expansions of therapies like Opzelura, povorcitinib and Niktimvo in indications such as atopic dermatitis, vitiligo, hidradenitis suppurativa and GVHD remain a key driver for Incyte, with updated 2026 guidance pointing to higher total net sales of US$5.13 to 5.26b and Opzelura net sales of US$1.05 to 1.10b, which helps frame expectations for future revenue and earnings.

See why 57 investors see Incyte as 9% undervalued.

Result: Fair Value of $128.48 (UNDERVALUED)

Still, the Incyte story can shift quickly if late stage trials disappoint, or if rising R&D and acquisition costs squeeze margins harder than expected.

Find out about the key risks to this Incyte narrative.

Next Steps

Mixed views like this can be useful if you use them as a prompt rather than a script, so move quickly, review the underlying numbers and weigh both the 3 key rewards and 2 important warning signs

Looking for more Incyte-sized investment ideas?

Do not stop at Incyte. Use the Simply Wall Street Screener to hunt for fresh opportunities so you are not chasing the same crowded stories as everyone else.

• Target resilient income by focusing on businesses that aim to combine stability with higher yields through the 6 dividend fortresses.
• Zero in on quality at a discount by scanning for financially strong companies trading below their estimated worth using the 26 high quality undervalued stocks.
• Shield your portfolio from shocks by concentrating on businesses with steadier risk profiles via the 32 resilient stocks with low risk scores.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com